Revance Therapeutics Stock Price, News & Analysis (NASDAQ:RVNC) $7.09 +0.04 (+0.57%) (As of 12/7/2023 ET) Add Compare Share Share Today's Range$6.93▼$7.2050-Day Range$5.81▼$11.4752-Week Range$5.72▼$37.98Volume1.16 million shsAverage Volume1.62 million shsMarket Capitalization$622.59 millionP/E RatioN/ADividend YieldN/APrice Target$25.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Revance Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside257.3% Upside$25.33 Price TargetShort InterestBearish16.66% of Shares Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.05) to ($2.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 starsMedical Sector205th out of 960 stocksPharmaceutical Preparations Industry53rd out of 381 stocks 4.4 Analyst's Opinion Consensus RatingRevance Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.33, Revance Therapeutics has a forecasted upside of 257.3% from its current price of $7.09.Amount of Analyst CoverageRevance Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.66% of the outstanding shares of Revance Therapeutics have been sold short.Short Interest Ratio / Days to CoverRevance Therapeutics has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Revance Therapeutics has recently increased by 13.15%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRevance Therapeutics does not currently pay a dividend.Dividend GrowthRevance Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRevance Therapeutics has received a 74.80% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Revance Therapeutics is -0.88. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 3 people have searched for RVNC on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Revance Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Revance Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.10% of the stock of Revance Therapeutics is held by insiders.Percentage Held by Institutions93.28% of the stock of Revance Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Revance Therapeutics are expected to grow in the coming year, from ($3.05) to ($2.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revance Therapeutics is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revance Therapeutics is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRevance Therapeutics has a P/B Ratio of 47.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Revance Therapeutics Stock (NASDAQ:RVNC)Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.Read More RVNC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVNC Stock News HeadlinesNovember 29, 2023 | seekingalpha.comRevance Therapeutics: Not Even Daxxify Can Treat Investor Frown LinesNovember 28, 2023 | americanbankingnews.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Given Consensus Rating of "Moderate Buy" by AnalystsDecember 8, 2023 | Financial Alphas (Ad)Recent Reports Are A Wake-Up Call For InvestorsAs the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.November 22, 2023 | markets.businessinsider.comWhat 10 Analyst Ratings Have To Say About Revance TherapeuticsNovember 10, 2023 | markets.businessinsider.comRevance Therapeutics Maintains Buy Rating Despite Decreased Share Value: New Pricing Strategy Shows Promising ResultsNovember 10, 2023 | markets.businessinsider.comRevance Therapeutics: Adapting Strategy and Promising Outlook Justify Buy RatingNovember 10, 2023 | finance.yahoo.comAnalysts Just Slashed Their Revance Therapeutics, Inc. (NASDAQ:RVNC) EPS NumbersNovember 9, 2023 | finance.yahoo.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2023 Earnings Call TranscriptDecember 8, 2023 | Financial Alphas (Ad)Recent Reports Are A Wake-Up Call For InvestorsAs the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.November 9, 2023 | finance.yahoo.comQ3 2023 Revance Therapeutics Inc Earnings CallNovember 8, 2023 | finance.yahoo.comRevance Therapeutics, Inc. (RVNC) Reports Q3 Earnings: What Key Metrics Have to SayNovember 8, 2023 | finance.yahoo.comRevance Appoints Erica Jordan as Chief Commercial Officer, AestheticsNovember 8, 2023 | finance.yahoo.comRevance Reports Third Quarter 2023 Financial Results, Provides Corporate UpdateNovember 1, 2023 | finance.yahoo.comRevance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023October 26, 2023 | finance.yahoo.comDAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best InventionsOctober 24, 2023 | msn.comBarclays Maintains Revance Therapeutics (RVNC) Overweight RecommendationSeptember 22, 2023 | 247wallst.comGoldman Sachs Maintains Revance Therapeutics Buy RecommendationSeptember 20, 2023 | benzinga.comDiscontinuation Of Opul Business Weighs On Botox Rival Revance Therapeutics: Analyst Sees Non-Cash Impairment Charge In MillionsSeptember 19, 2023 | seekingalpha.comRevance down 16% as investor day update fails to impressSeptember 19, 2023 | markets.businessinsider.comWhat's Going On With Botox Rival Revance Therapeutics' Stock Today?September 19, 2023 | finance.yahoo.comRevance Provides Corporate Update at Investor DaySeptember 18, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Revance Therapeutics (RVNC) and PTC Therapeutics (PTCT)September 15, 2023 | msn.comRevance Therapeutics: Impressive Sales Growth/Concerning Cash BurnSeptember 15, 2023 | seekingalpha.comRevance's FDA Nod: Beauty, Brains, And Balance SheetsSeptember 6, 2023 | finance.yahoo.comRevance Therapeutics (RVNC): A Smart Investment or a Value Trap? An In-Depth ExplorationAugust 22, 2023 | finance.yahoo.comRevance to Host Investor Day on September 19, 2023August 22, 2023 | finance.yahoo.com‘Load Up,’ Says Goldman Sachs About These 2 ‘Strong Buy’ StocksSee More Headlines Receive RVNC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today12/07/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RVNC CUSIPN/A CIK1479290 Webwww.revance.com Phone(615) 724-7755Fax510-742-3401Employees534Year FoundedN/APrice Target and Rating Average Stock Price Target$25.33 High Stock Price Target$42.00 Low Stock Price Target$12.00 Potential Upside/Downside+257.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-356,420,000.00 Net Margins-193.42% Pretax Margin-193.28% Return on Equity-903.28% Return on Assets-59.67% Debt Debt-to-Equity Ratio14.20 Current Ratio4.73 Quick Ratio4.17 Sales & Book Value Annual Sales$214.16 million Price / Sales2.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book47.27Miscellaneous Outstanding Shares87,813,000Free Float84,652,000Market Cap$622.59 million OptionableOptionable Beta0.83 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Mark J. Foley (Age 58)CEO & Director Comp: $1.33MMr. Dustin S. Sjuts (Age 43)President Comp: $911.67kMr. Tobin C. Schilke (Age 48)CFO & Principal Accounting Officer Comp: $753.68kMr. Dwight Moxie (Age 47)Senior VP, General Counsel & Corporate Secretary Comp: $743.77kJessica SerraHead of Investor Relations & ESGMs. Jeanie D. HerbertSenior Director of Investor Relations & Corporate CommunicationsMs. Taryn ConwayVice President of MarketingMs. Amie KrauseChief People OfficerDr. Conor GallagherHead of Medical Affairs & AestheticsDr. David A. Hollander M.B.A. (Age 49)M.D., Chief Medical Officer More ExecutivesKey CompetitorsZymeworksNYSE:ZYMECentessa PharmaceuticalsNASDAQ:CNTAPharvarisNASDAQ:PHVSWave Life SciencesNASDAQ:WVEAcelyrinNASDAQ:SLRNView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 37,131 shares on 12/1/2023Ownership: 1.233%Deutsche Bank AGBought 5,200 shares on 11/24/2023Ownership: 0.051%Polar Capital Holdings PlcSold 7,531 shares on 11/22/2023Ownership: 4.738%Public Sector Pension Investment BoardSold 78,000 shares on 11/22/2023Ownership: 0.200%Walleye Capital LLCSold 1,100 shares on 11/21/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions RVNC Stock Analysis - Frequently Asked Questions Should I buy or sell Revance Therapeutics stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RVNC shares. View RVNC analyst ratings or view top-rated stocks. What is Revance Therapeutics' stock price target for 2024? 8 Wall Street research analysts have issued 1-year price objectives for Revance Therapeutics' shares. Their RVNC share price targets range from $12.00 to $42.00. On average, they anticipate the company's stock price to reach $25.33 in the next year. This suggests a possible upside of 257.3% from the stock's current price. View analysts price targets for RVNC or view top-rated stocks among Wall Street analysts. How have RVNC shares performed in 2023? Revance Therapeutics' stock was trading at $18.46 on January 1st, 2023. Since then, RVNC shares have decreased by 61.6% and is now trading at $7.09. View the best growth stocks for 2023 here. When is Revance Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our RVNC earnings forecast. How were Revance Therapeutics' earnings last quarter? Revance Therapeutics, Inc. (NASDAQ:RVNC) issued its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.02) by $0.28. The biopharmaceutical company had revenue of $56.78 million for the quarter, compared to the consensus estimate of $58.49 million. Revance Therapeutics had a negative net margin of 193.42% and a negative trailing twelve-month return on equity of 903.28%. What ETFs hold Revance Therapeutics' stock? ETFs with the largest weight of Revance Therapeutics (NASDAQ:RVNC) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What is Mark Foley's approval rating as Revance Therapeutics' CEO? 7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among the company's employees. What other stocks do shareholders of Revance Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO). Who are Revance Therapeutics' major shareholders? Revance Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Polar Capital Holdings Plc (4.74%), Invesco Ltd. (3.31%), FMR LLC (2.16%), Rubric Capital Management LP (1.82%), Rubric Capital Management LP (1.82%) and Wellington Management Group LLP (1.23%). Insiders that own company stock include Angus C Russell, Aubrey Rankin, Carey Oconnor Kolaja, Dustin S Sjuts, Dwight Moxie, Mark J Foley and Tobin Schilke. View institutional ownership trends. How do I buy shares of Revance Therapeutics? Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:RVNC) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revance Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.